Background: Recent meta-analyses showed deterioration of glucose metabolism following administration of statins. Limited information is available on the glycemic effect of a recently approved statin, pitavastatin (PTA). In Phase 3 non-inferiority trials, LDL-C reductions with PTA 2 mg and 4 mg were comparable to simvastatin (SMV) 20 mg and 40 mg, respectively. This post-hoc analysis examined the short-and long-term effects of PTA 4 mg (maximum dose) compared with SMV 40 mg (recently approved maximum dose) on changes in fasting plasma glucose (FPG) in patients with primary hyperlipidemia (PH) or mixed dyslipidemia (MD) and ≥2 risk factors for coronary heart disease (CHD).
